Drug Profile

Utreglutide - Sun Pharmaceutical Industries

Alternative Names: GL-0034

Latest Information Update: 31 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sun Pharmaceutical Industries
Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies
Mechanism of Action Glucagon-like peptide-1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Obesity
Preclinical Non-alcoholic fatty liver disease
No development reported Type 2 diabetes mellitus

Most Recent Events

19 Nov 2024 Updated data from a phase I trial in Obesity presented at the American Heart Association Scientific Sessions 2024 (AHA-2024)
09 Sep 2024 Pharmacodynamics data from a phase I trial (In volunteers) presented at the 60^th Annual Meeting of the European Association for the Study of Diabetes (EASD-2024)
09 Sep 2024 Pharmacodynamics data from a preclinical trial in Type 2 diabetes mellitus presented at the 60^th Annual Meeting of the European Association for the Study of Diabetes (EASD-2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com